CorMedix Inc. to Present at the 20th Annual Needham Virtual Healthcare Conference
April 07, 2021 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 30, 2021 16:05 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update on March 30
March 23, 2021 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Approved to Sell $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program
March 15, 2021 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Announces Contract Extension of Liz Masson-Hurlburt as Executive Vice President and Head of Clinical Operations
March 11, 2021 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. to Host Regulatory Update Conference Call
March 08, 2021 17:00 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Receives Complete Response Letter From FDA for DefenCath™ Catheter Lock Solution
March 01, 2021 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange
January 21, 2021 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the...
CorMedix Inc. Announces FDA Decision That Advisory Committee Meeting for New Drug Application for Defencath is Not Needed
November 18, 2020 08:30 ET
|
CorMedix, Inc.
PDUFA date remains February 28, 2021Potentially the first antibacterial and antifungal catheter lock solution in the US to prevent catheter related infections in hemodialysis patients BERKELEY...
CorMedix Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update
November 05, 2020 16:05 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the...